Recent Advances in Antibody Therapeutics
Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinica...
Saved in:
| Sonstige: | |
|---|---|
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (238 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993545250904498 |
|---|---|
| ctrlnum |
(CKB)5690000000012042 (oapen)https://directory.doabooks.org/handle/20.500.12854/87408 (EXLCZ)995690000000012042 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Heo, Yong-Seok edt Recent Advances in Antibody Therapeutics Basel MDPI - Multidisciplinary Digital Publishing Institute 2022 1 electronic resource (238 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies English Research & information: general bicssc Chemistry bicssc interleukin 33 ST2 receptor scFv C2_2E12 bladder cancer antibodies immune checkpoint inhibitors antibody-drug conjugates sacituzumab govitecan enfortumab vedotin erdafitinib cost-effectiveness G protein-coupled receptor membrane protein antigen therapeutic antibody anti-angiogenesis delta-like ligand irinotecan paclitaxel VEGF SARS-CoV-2 spike protein receptor-binding domain phage display monoclonal antibody cytomegalovirus peptide/major histocompatibility complex class I complex T-cell-receptor-like antibody affinity maturation yeast surface display combinatorial antibody library agonist antibody cell fate bispecific antibodies bioassays mechanisms of action binding assays potency assays atherosclerosis inflammation antibody therapy blood-brain barrier antibody pharmacokinetics disposition biochemical and physicochemical properties Fc binding receptor-mediated transcytosis brain shuttle molecular Trojan horse transferrin anti-cancer antibody antibody engineering biophysical properties computational methods research cell bank antibody therapeutics recombinant antibodies intracellular antibodies single-chain antibody fragment nanobody Human papillomaviruses HPV oncoproteins HPV-associated cancer HPV cancer therapy asthma refractory asthma biomarker 3-0365-4353-8 3-0365-4354-6 Heo, Yong-Seok oth |
| language |
English |
| format |
eBook |
| author2 |
Heo, Yong-Seok |
| author_facet |
Heo, Yong-Seok |
| author2_variant |
y s h ysh |
| author2_role |
Sonstige |
| title |
Recent Advances in Antibody Therapeutics |
| spellingShingle |
Recent Advances in Antibody Therapeutics |
| title_full |
Recent Advances in Antibody Therapeutics |
| title_fullStr |
Recent Advances in Antibody Therapeutics |
| title_full_unstemmed |
Recent Advances in Antibody Therapeutics |
| title_auth |
Recent Advances in Antibody Therapeutics |
| title_new |
Recent Advances in Antibody Therapeutics |
| title_sort |
recent advances in antibody therapeutics |
| publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
| publishDate |
2022 |
| physical |
1 electronic resource (238 p.) |
| isbn |
3-0365-4353-8 3-0365-4354-6 |
| illustrated |
Not Illustrated |
| work_keys_str_mv |
AT heoyongseok recentadvancesinantibodytherapeutics |
| status_str |
n |
| ids_txt_mv |
(CKB)5690000000012042 (oapen)https://directory.doabooks.org/handle/20.500.12854/87408 (EXLCZ)995690000000012042 |
| carrierType_str_mv |
cr |
| is_hierarchy_title |
Recent Advances in Antibody Therapeutics |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1796649052825190400 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04012nam-a2201129z--4500</leader><controlfield tag="001">993545250904498</controlfield><controlfield tag="005">20231214133255.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202207s2022 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5690000000012042</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/87408</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995690000000012042</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Heo, Yong-Seok</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recent Advances in Antibody Therapeutics</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (238 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Since first receiving approval in 1986, antibody-based therapeutics have been the most successful modality for the treatment of various diseases. This Special Issue of IJMS, “Recent Advances in Antibody Therapeutics”, presents leading-edge articles and reviews for discovery, development, and clinical applications of therapeutic antibodies, covering antibody drug conjugates (ADCs), GPCR-targeting antibodies, a functional antibody screening, bioassay of bispecific antibodies, antibody applications for cardiovascular diseases, antibody delivery to CNS, etc. The excellent studies in this Special Issue would valuable insight for scientists and clinicians in the field of therapeutic antibodies</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Research & information: general</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemistry</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interleukin 33</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ST2 receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">scFv</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">C2_2E12</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bladder cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody-drug conjugates</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sacituzumab govitecan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">enfortumab vedotin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">erdafitinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cost-effectiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">G protein-coupled receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">membrane protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antigen</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapeutic antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-angiogenesis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">delta-like ligand</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">irinotecan</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">paclitaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VEGF</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">SARS-CoV-2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">spike protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">receptor-binding domain</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phage display</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">monoclonal antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cytomegalovirus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">peptide/major histocompatibility complex class I complex</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T-cell-receptor-like antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">affinity maturation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">yeast surface display</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">combinatorial antibody library</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">agonist antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell fate</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bispecific antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bioassays</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mechanisms of action</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">binding assays</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">potency assays</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">atherosclerosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">inflammation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">blood-brain barrier</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pharmacokinetics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">disposition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biochemical and physicochemical properties</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fc binding</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">receptor-mediated transcytosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">brain shuttle</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">molecular Trojan horse</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transferrin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">anti-cancer antibody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biophysical properties</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">computational methods</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">research cell bank</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">antibody therapeutics</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recombinant antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">intracellular antibodies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">single-chain antibody fragment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nanobody</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Human papillomaviruses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HPV oncoproteins</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HPV-associated cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HPV cancer therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">asthma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">refractory asthma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4353-8</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-4354-6</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heo, Yong-Seok</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:48:55 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-07-14 08:50:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337857830004498&Force_direct=true</subfield><subfield code="Z">5337857830004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337857830004498</subfield></datafield></record></collection> |